ID   CLUS_HUMAN              Reviewed;         449 AA.
AC   P10909; B2R9Q1; B3KSE6; P11380; P11381; Q2TU75; Q5HYC1; Q7Z5B9;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   28-JUN-2023, entry version 244.
DE   RecName: Full=Clusterin;
DE   AltName: Full=Aging-associated gene 4 protein {ECO:0000303|Ref.20};
DE   AltName: Full=Apolipoprotein J {ECO:0000303|PubMed:2387851};
DE            Short=Apo-J;
DE   AltName: Full=Complement cytolysis inhibitor {ECO:0000303|PubMed:2780565};
DE            Short=CLI {ECO:0000303|PubMed:2780565};
DE   AltName: Full=Complement-associated protein SP-40,40 {ECO:0000303|PubMed:1903064, ECO:0000303|PubMed:2721499};
DE   AltName: Full=Ku70-binding protein 1;
DE   AltName: Full=NA1/NA2 {ECO:0000303|PubMed:1903064};
DE   AltName: Full=Sulfated glycoprotein 2 {ECO:0000303|PubMed:1924317};
DE            Short=SGP-2 {ECO:0000303|PubMed:1924317};
DE   AltName: Full=Testosterone-repressed prostate message 2 {ECO:0000250|UniProtKB:P05371};
DE            Short=TRPM-2 {ECO:0000303|PubMed:8181474};
DE   Contains:
DE     RecName: Full=Clusterin beta chain;
DE     AltName: Full=ApoJalpha {ECO:0000303|PubMed:1974459, ECO:0000303|PubMed:2387851};
DE     AltName: Full=Complement cytolysis inhibitor a chain {ECO:0000303|PubMed:2780565};
DE     AltName: Full=SP-40,40 beta-chain {ECO:0000303|PubMed:2721499};
DE   Contains:
DE     RecName: Full=Clusterin alpha chain;
DE     AltName: Full=ApoJbeta {ECO:0000303|PubMed:1974459, ECO:0000303|PubMed:2387851};
DE     AltName: Full=Complement cytolysis inhibitor b chain {ECO:0000303|PubMed:2780565};
DE     AltName: Full=SP-40,40 alpha-chain {ECO:0000303|PubMed:2721499};
DE   Flags: Precursor;
GN   Name=CLU {ECO:0000312|HGNC:HGNC:2095};
GN   Synonyms=APOJ {ECO:0000303|PubMed:2387851}, CLI
GN   {ECO:0000303|PubMed:2780565}, KUB1; ORFNames=AAG4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF N-TERMINUS,
RP   SUBUNIT, DISULFIDE BONDS, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   FUNCTION.
RC   TISSUE=Liver;
RX   PubMed=2780565; DOI=10.1073/pnas.86.18.7123;
RA   Jenne D.E., Tschopp J.;
RT   "Molecular structure and functional characterization of a human complement
RT   cytolysis inhibitor found in blood and seminal plasma: identity to sulfated
RT   glycoprotein 2, a constituent of rat testis fluid.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:7123-7127(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], PARTIAL NUCLEOTIDE SEQUENCE [MRNA]
RP   (ISOFORM 2), AND TISSUE SPECIFICITY.
RX   PubMed=8181474; DOI=10.1111/j.1432-1033.1994.tb18807.x;
RA   Wong P., Taillefer D., Lakins J., Pineault J., Chader G., Tenniswood M.;
RT   "Molecular characterization of human TRPM-2/clusterin, a gene associated
RT   with sperm maturation, apoptosis and neurodegeneration.";
RL   Eur. J. Biochem. 221:917-925(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 4 AND 6), SUBCELLULAR LOCATION, AND
RP   GLYCOSYLATION (ISOFORM 1).
RX   PubMed=24073260; DOI=10.1371/journal.pone.0075303;
RA   Prochnow H., Gollan R., Rohne P., Hassemer M., Koch-Brandt C.,
RA   Baiersdoerfer M.;
RT   "Non-secreted clusterin isoforms are translated in rare amounts from
RT   distinct human mRNA variants and do not affect Bax-mediated apoptosis or
RT   the NF-kappaB signaling pathway.";
RL   PLoS ONE 8:E75303-E75303(2013).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND PARTIAL NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Stomach, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Small intestine;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-317; ASN-328 AND
RP   LEU-396.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5), AND PARTIAL NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Spinal ganglion;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 23-33; 229-242; 303-317 AND 397-403, SUBUNIT, AND
RP   INTERACTION WITH APOA1.
RX   PubMed=1903064; DOI=10.1161/01.atv.11.3.645;
RA   James R.W., Hochstrasser A.-C., Borghini I., Martin B.M., Pometta D.,
RA   Hochstrasser D.F.;
RT   "Characterization of a human high density lipoprotein-associated protein,
RT   NA1/NA2. Identity with SP-40,40, an inhibitor of complement-mediated
RT   cytolysis.";
RL   Arterioscler. Thromb. 11:645-652(1991).
RN   [11]
RP   PROTEIN SEQUENCE OF 23-52 AND 228-257, SUBUNIT, DISULFIDE BOND, PROTEOLYTIC
RP   PROCESSING, GLYCOSYLATION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=2387851; DOI=10.1016/s0021-9258(18)77299-2;
RA   de Silva H., Stuart W.D., Park Y.B., Mao S.J.T., Gil C.M., Wetterau J.R.,
RA   Busch S.J., Harmony J.A.K.;
RT   "Purification and characterization of apolipoprotein J.";
RL   J. Biol. Chem. 265:14292-14297(1990).
RN   [12]
RP   PROTEIN SEQUENCE OF 23-41 AND 228-246, INTERACTION WITH APP, SUBCELLULAR
RP   LOCATION, DISULFIDE BOND, AND TISSUE SPECIFICITY.
RX   PubMed=8328966; DOI=10.1042/bj2930027;
RA   Ghiso J., Matsubara E., Koudinov A., Choi-Miura N.-H., Tomita M.,
RA   Wisniewski T., Frangione B.;
RT   "The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is
RT   complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement
RT   membrane-attack complex.";
RL   Biochem. J. 293:27-30(1993).
RN   [13]
RP   PROTEIN SEQUENCE OF 23-37 AND 228-242, AND INTERACTION WITH COMPLEMENT
RP   COMPLEX.
RX   PubMed=2601725; DOI=10.1016/0161-5890(89)90139-9;
RA   Choi N.H., Mazda T., Tomita M.;
RT   "A serum protein SP40,40 modulates the formation of membrane attack complex
RT   of complement on erythrocytes.";
RL   Mol. Immunol. 26:835-840(1989).
RN   [14]
RP   PROTEIN SEQUENCE OF 23-33 AND 228-240, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=3154963;
RA   Hochstrasser A.-C., James R.W., Martin B.M., Harrington M.,
RA   Hochstrasser D.F., Pometta D., Merril C.R.;
RT   "HDL particle associated proteins in plasma and cerebrospinal fluid:
RT   identification and partial sequencing.";
RL   Appl. Theor. Electrophor. 1:73-76(1988).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 34-449 (ISOFORMS 1/2/4/5/6), PROTEIN SEQUENCE
RP   OF 124-127; 195-221; 254-268; 336-353 AND 442-449, AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=1974459; DOI=10.1021/bi00474a025;
RA   de Silva H.V., Harmony J.A.K., Stuart W.D., Gil C.M., Robbins J.;
RT   "Apolipoprotein J: structure and tissue distribution.";
RL   Biochemistry 29:5380-5389(1990).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 61-449.
RC   TISSUE=Astrocytoma;
RX   PubMed=1924317; DOI=10.1073/pnas.88.19.8577;
RA   Danik M., Chabot J.G., Mercier C., Benabid A.L., Chauvin C., Quirion R.,
RA   Suh M.;
RT   "Human gliomas and epileptic foci express high levels of a mRNA related to
RT   rat testicular sulfated glycoprotein 2, a purported marker of cell death.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:8577-8581(1991).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 140-449.
RC   TISSUE=Fetal liver;
RA   Glew M.D., Kirszbaum L., Bozas S.E., Walker I.D.;
RL   Submitted (JAN-1993) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND PARTIAL PROTEIN
RP   SEQUENCE.
RC   TISSUE=Liver;
RX   PubMed=2721499; DOI=10.1002/j.1460-2075.1989.tb03430.x;
RA   Kirszbaum L., Sharpe J.A., Murphy B., D'Apice J.F.A., Classon B.,
RA   Hudson P., Walker I.D.;
RT   "Molecular cloning and characterization of the novel, human complement-
RT   associated protein, SP-40,40: a link between the complement and
RT   reproductive systems.";
RL   EMBO J. 8:711-718(1989).
RN   [19]
RP   PARTIAL PROTEIN SEQUENCE, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-86;
RP   ASN-103; ASN-145; ASN-291; ASN-354 AND ASN-374.
RX   PubMed=1551440; DOI=10.1016/0014-5793(92)80330-j;
RA   Kirszbaum L., Bozas S.E., Walker I.D.;
RT   "SP-40,40, a protein involved in the control of the complement pathway,
RT   possesses a unique array of disulphide bridges.";
RL   FEBS Lett. 297:70-76(1992).
RN   [20]
RP   PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Kim J.W.;
RT   "Identification of human aging-associated gene.";
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [21]
RP   INTERACTION WITH APOA1.
RX   PubMed=1742316; DOI=10.1016/0005-2760(91)90167-g;
RA   Ehnholm C., Bozas S.E., Tenkanen H., Kirszbaum L., Metso J., Murphy B.,
RA   Walker I.D.;
RT   "The apolipoprotein A-I binding protein of placenta and the SP-40,40
RT   protein of human blood are different proteins which both bind to
RT   apolipoprotein A-I.";
RL   Biochim. Biophys. Acta 1086:255-260(1991).
RN   [22]
RP   DISULFIDE BONDS.
RX   PubMed=1491011; DOI=10.1093/oxfordjournals.jbchem.a123938;
RA   Choi-Miura N.H., Takahashi Y., Nakano Y., Tobe T., Tomita M.;
RT   "Identification of the disulfide bonds in human plasma protein SP-40,40
RT   (apolipoprotein-J).";
RL   J. Biochem. 112:557-561(1992).
RN   [23]
RP   INTERACTION WITH PON1, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=8292612; DOI=10.1021/bi00169a026;
RA   Kelso G.J., Stuart W.D., Richter R.J., Furlong C.E., Jordan-Starck T.C.,
RA   Harmony J.A.K.;
RT   "Apolipoprotein J is associated with paraoxonase in human plasma.";
RL   Biochemistry 33:832-839(1994).
RN   [24]
RP   INTERACTION WITH TGFBR2 AND ACVR1.
RX   PubMed=8555189; DOI=10.1021/bi951880a;
RA   Reddy K.B., Karode M.C., Harmony A.K., Howe P.H.;
RT   "Interaction of transforming growth factor beta receptors with
RT   apolipoprotein J/clusterin.";
RL   Biochemistry 35:309-314(1996).
RN   [25]
RP   GLYCOSYLATION AT ASN-86; ASN-103; ASN-145; ASN-291; ASN-354 AND ASN-374.
RC   TISSUE=Serum;
RX   PubMed=9336835; DOI=10.1002/pro.5560061007;
RA   Kapron J.T., Hilliard G.M., Lakins J.N., Tenniswood M.P., West K.A.,
RA   Carr S.A., Crabb J.W.;
RT   "Identification and characterization of glycosylation sites in human serum
RT   clusterin.";
RL   Protein Sci. 6:2120-2133(1997).
RN   [26]
RP   FUNCTION, SUBCELLULAR LOCATION, ABSENCE OF ATPASE ACTIVITY, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=11123922; DOI=10.1021/bi002189x;
RA   Poon S., Easterbrook-Smith S.B., Rybchyn M.S., Carver J.A., Wilson M.R.;
RT   "Clusterin is an ATP-independent chaperone with very broad substrate
RT   specificity that stabilizes stressed proteins in a folding-competent
RT   state.";
RL   Biochemistry 39:15953-15960(2000).
RN   [27]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=12047389; DOI=10.1046/j.1432-1033.2002.02957.x;
RA   Hatters D.M., Wilson M.R., Easterbrook-Smith S.B., Howlett G.J.;
RT   "Suppression of apolipoprotein C-II amyloid formation by the extracellular
RT   chaperone, clusterin.";
RL   Eur. J. Biochem. 269:2789-2794(2002).
RN   [28]
RP   FUNCTION, SUBUNIT, AND CIRCULAR DICHROISM.
RX   PubMed=12176985; DOI=10.1074/jbc.m204855200;
RA   Poon S., Rybchyn M.S., Easterbrook-Smith S.B., Carver J.A., Pankhurst G.J.,
RA   Wilson M.R.;
RT   "Mildly acidic pH activates the extracellular molecular chaperone
RT   clusterin.";
RL   J. Biol. Chem. 277:39532-39540(2002).
RN   [29]
RP   ALTERNATIVE SPLICING, IDENTIFICATION OF ISOFORM 4, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=12551933; DOI=10.1074/jbc.m209233200;
RA   Leskov K.S., Klokov D.Y., Li J., Kinsella T.J., Boothman D.A.;
RT   "Synthesis and functional analyses of nuclear clusterin, a cell death
RT   protein.";
RL   J. Biol. Chem. 278:11590-11600(2003).
RN   [30]
RP   FUNCTION.
RX   PubMed=12882985; DOI=10.1074/jbc.c300252200;
RA   Santilli G., Aronow B.J., Sala A.;
RT   "Essential requirement of apolipoprotein J (clusterin) signaling for
RT   IkappaB expression and regulation of NF-kappaB activity.";
RL   J. Biol. Chem. 278:38214-38219(2003).
RN   [31]
RP   GLYCOSYLATION AT ASN-354.
RC   TISSUE=Serum;
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [32]
RP   INTERACTION WITH CLUAP1.
RX   PubMed=15480429; DOI=10.1038/sj.onc.1208100;
RA   Takahashi M., Lin Y.-M., Nakamura Y., Furukawa Y.;
RT   "Isolation and characterization of a novel gene CLUAP1 whose expression is
RT   frequently upregulated in colon cancer.";
RL   Oncogene 23:9289-9294(2004).
RN   [33]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-354 AND ASN-374.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [34]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-86; ASN-103; ASN-145; ASN-291;
RP   ASN-354 AND ASN-374.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [35]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH BAX.
RX   PubMed=16113678; DOI=10.1038/ncb1291;
RA   Zhang H., Kim J.K., Edwards C.A., Xu Z., Taichman R., Wang C.Y.;
RT   "Clusterin inhibits apoptosis by interacting with activated Bax.";
RL   Nat. Cell Biol. 7:909-915(2005).
RN   [36]
RP   INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16548883; DOI=10.1111/j.1462-5822.2005.00644.x;
RA   Leong W.F., Chow V.T.;
RT   "Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal
RT   differential cellular gene expression in response to enterovirus 71
RT   infection.";
RL   Cell. Microbiol. 8:565-580(2006).
RN   [37]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-374.
RC   TISSUE=Saliva;
RX   PubMed=16740002; DOI=10.1021/pr050492k;
RA   Ramachandran P., Boontheung P., Xie Y., Sondej M., Wong D.T., Loo J.A.;
RT   "Identification of N-linked glycoproteins in human saliva by glycoprotein
RT   capture and mass spectrometry.";
RL   J. Proteome Res. 5:1493-1503(2006).
RN   [38]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-374.
RC   TISSUE=Platelet;
RX   PubMed=16263699; DOI=10.1074/mcp.m500324-mcp200;
RA   Lewandrowski U., Moebius J., Walter U., Sickmann A.;
RT   "Elucidation of N-glycosylation sites on human platelet proteins: a
RT   glycoproteomic approach.";
RL   Mol. Cell. Proteomics 5:226-233(2006).
RN   [39]
RP   FUNCTION, SUBUNIT, INTERACTION WITH LRP2, GLYCOSYLATION, SUBCELLULAR
RP   LOCATION, IDENTIFICATION BY MASS SPECTROMETRY, CIRCULAR DICHROISM, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=17260971; DOI=10.1021/bi062082v;
RA   Stewart E.M., Aquilina J.A., Easterbrook-Smith S.B., Murphy-Durland D.,
RA   Jacobsen C., Moestrup S., Wilson M.R.;
RT   "Effects of glycosylation on the structure and function of the
RT   extracellular chaperone clusterin.";
RL   Biochemistry 46:1412-1422(2007).
RN   [40]
RP   FUNCTION, INDUCTION, PROTEASOMAL DEGRADATION, AND SUBCELLULAR LOCATION.
RX   PubMed=17689225; DOI=10.1016/j.bbadis.2007.06.004;
RA   Ranney M.K., Ahmed I.S., Potts K.R., Craven R.J.;
RT   "Multiple pathways regulating the anti-apoptotic protein clusterin in
RT   breast cancer.";
RL   Biochim. Biophys. Acta 1772:1103-1111(2007).
RN   [41]
RP   IDENTIFICATION IN A COMPLEX WITH LTF; SEMG1 AND EPPIN.
RX   PubMed=17567961; DOI=10.1095/biolreprod.107.060194;
RA   Wang Z., Widgren E.E., Richardson R.T., O'Rand M.G.;
RT   "Characterization of an eppin protein complex from human semen and
RT   spermatozoa.";
RL   Biol. Reprod. 77:476-484(2007).
RN   [42]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17412999; DOI=10.1096/fj.06-7986com;
RA   Yerbury J.J., Poon S., Meehan S., Thompson B., Kumita J.R., Dobson C.M.,
RA   Wilson M.R.;
RT   "The extracellular chaperone clusterin influences amyloid formation and
RT   toxicity by interacting with prefibrillar structures.";
RL   FASEB J. 21:2312-2322(2007).
RN   [43]
RP   ALTERNATIVE SPLICING, IDENTIFICATION OF ISOFORMS 1 AND 2, AND INDUCTION BY
RP   ANDROGEN.
RX   PubMed=17148459; DOI=10.1074/jbc.m608162200;
RA   Cochrane D.R., Wang Z., Muramaki M., Gleave M.E., Nelson C.C.;
RT   "Differential regulation of clusterin and its isoforms by androgens in
RT   prostate cells.";
RL   J. Biol. Chem. 282:2278-2287(2007).
RN   [44]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=17407782; DOI=10.1016/j.jmb.2007.02.095;
RA   Kumita J.R., Poon S., Caddy G.L., Hagan C.L., Dumoulin M., Yerbury J.J.,
RA   Stewart E.M., Robinson C.V., Wilson M.R., Dobson C.M.;
RT   "The extracellular chaperone clusterin potently inhibits human lysozyme
RT   amyloid formation by interacting with prefibrillar species.";
RL   J. Mol. Biol. 369:157-167(2007).
RN   [45]
RP   ALTERNATIVE SPLICING, IDENTIFICATION OF ISOFORMS 1; 2 AND 5, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=17322305; DOI=10.1074/mcp.m600261-mcp200;
RA   Andersen C.L., Schepeler T., Thorsen K., Birkenkamp-Demtroder K.,
RA   Mansilla F., Aaltonen L.A., Laurberg S., Orntoft T.F.;
RT   "Clusterin expression in normal mucosa and colorectal cancer.";
RL   Mol. Cell. Proteomics 6:1039-1048(2007).
RN   [46]
RP   SUBCELLULAR LOCATION, INTERACTION WITH SYVN1, AND UBIQUITINATION.
RX   PubMed=17451556; DOI=10.1111/j.1600-0854.2007.00549.x;
RA   Nizard P., Tetley S., Le Drean Y., Watrin T., Le Goff P., Wilson M.R.,
RA   Michel D.;
RT   "Stress-induced retrotranslocation of clusterin/ApoJ into the cytosol.";
RL   Traffic 8:554-565(2007).
RN   [47]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-291 AND ASN-374.
RC   TISSUE=Milk;
RX   PubMed=18780401; DOI=10.1002/pmic.200701057;
RA   Picariello G., Ferranti P., Mamone G., Roepstorff P., Addeo F.;
RT   "Identification of N-linked glycoproteins in human milk by hydrophilic
RT   interaction liquid chromatography and mass spectrometry.";
RL   Proteomics 8:3833-3847(2008).
RN   [48]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=19535339; DOI=10.1074/jbc.m109.033688;
RA   Wyatt A.R., Yerbury J.J., Wilson M.R.;
RT   "Structural characterization of clusterin-chaperone client protein
RT   complexes.";
RL   J. Biol. Chem. 284:21920-21927(2009).
RN   [49]
RP   FUNCTION, SUBCELLULAR LOCATION, AND UBIQUITINATION.
RX   PubMed=19137541; DOI=10.1002/jcp.21671;
RA   Rizzi F., Caccamo A.E., Belloni L., Bettuzzi S.;
RT   "Clusterin is a short half-life, poly-ubiquitinated protein, which controls
RT   the fate of prostate cancer cells.";
RL   J. Cell. Physiol. 219:314-323(2009).
RN   [50]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-86; ASN-103; ASN-145; ASN-354
RP   AND ASN-374.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [51]
RP   GLYCOSYLATION AT ASN-86 AND ASN-374.
RX   PubMed=19139490; DOI=10.1074/mcp.m800504-mcp200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F., Zheng Z.B.,
RA   Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y., Zhang Y.K., Deng Y.L.,
RA   Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core fucosylated
RT   glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [52]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-374, AND STRUCTURE OF
RP   CARBOHYDRATES.
RC   TISSUE=Cerebrospinal fluid;
RX   PubMed=19838169; DOI=10.1038/nmeth.1392;
RA   Nilsson J., Rueetschi U., Halim A., Hesse C., Carlsohn E., Brinkmalm G.,
RA   Larson G.;
RT   "Enrichment of glycopeptides for glycan structure and attachment site
RT   identification.";
RL   Nat. Methods 6:809-811(2009).
RN   [53]
RP   FUNCTION.
RX   PubMed=19996109; DOI=10.1074/jbc.m109.079566;
RA   Wyatt A.R., Wilson M.R.;
RT   "Identification of human plasma proteins as major clients for the
RT   extracellular chaperone clusterin.";
RL   J. Biol. Chem. 285:3532-3539(2010).
RN   [54]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH COMMD1; UBIQUITIN; CUL1
RP   AND BTRC, AND IDENTIFICATION IN A E3 UBIQUITIN-PROTEIN LIGASE COMPLEX.
RX   PubMed=20068069; DOI=10.1158/1541-7786.mcr-09-0277;
RA   Zoubeidi A., Ettinger S., Beraldi E., Hadaschik B., Zardan A., Klomp L.W.,
RA   Nelson C.C., Rennie P.S., Gleave M.E.;
RT   "Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB
RT   activity in prostate cancer cells.";
RL   Mol. Cancer Res. 8:119-130(2010).
RN   [55]
RP   FUNCTION.
RX   PubMed=21505792; DOI=10.1007/s00018-011-0684-8;
RA   Wyatt A.R., Yerbury J.J., Berghofer P., Greguric I., Katsifis A.,
RA   Dobson C.M., Wilson M.R.;
RT   "Clusterin facilitates in vivo clearance of extracellular misfolded
RT   proteins.";
RL   Cell. Mol. Life Sci. 68:3919-3931(2011).
RN   [56]
RP   INTERACTION WITH BCL2L1, AND FUNCTION.
RX   PubMed=21567405; DOI=10.1002/jcp.22836;
RA   Kim N., Yoo J.C., Han J.Y., Hwang E.M., Kim Y.S., Jeong E.Y., Sun C.H.,
RA   Yi G.S., Roh G.S., Kim H.J., Kang S.S., Cho G.J., Park J.Y., Choi W.S.;
RT   "Human nuclear clusterin mediates apoptosis by interacting with Bcl-XL
RT   through C-terminal coiled coil domain.";
RL   J. Cell. Physiol. 227:1157-1167(2012).
RN   [57]
RP   INTERACTION WITH HSPA5, SUBCELLULAR LOCATION, MUTAGENESIS OF ASN-86;
RP   ASN-103; ASN-145; ASN-291; ASN-354 AND ASN-374, GLYCOSYLATION, AND
RP   FUNCTION.
RX   PubMed=22689054; DOI=10.1038/onc.2012.212;
RA   Li N., Zoubeidi A., Beraldi E., Gleave M.E.;
RT   "GRP78 regulates clusterin stability, retrotranslocation and mitochondrial
RT   localization under ER stress in prostate cancer.";
RL   Oncogene 32:1933-1942(2013).
RN   [58]
RP   GLYCOSYLATION, PROTEOLYTIC CLEAVAGE, MUTAGENESIS OF VAL-226 AND ARG-227,
RP   AND SITE.
RX   PubMed=25402950; DOI=10.1159/000366365;
RA   Rohne P., Prochnow H., Wolf S., Renner B., Koch-Brandt C.;
RT   "The chaperone activity of clusterin is dependent on glycosylation and
RT   redox environment.";
RL   Cell. Physiol. Biochem. 34:1626-1639(2014).
RN   [59]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-133 AND SER-396, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [60]
RP   INTERACTION WITH VLDLR AND LRP8.
RX   PubMed=24381170; DOI=10.1074/jbc.m113.529271;
RA   Leeb C., Eresheim C., Nimpf J.;
RT   "Clusterin is a ligand for apolipoprotein E receptor 2 (ApoER2) and very
RT   low density lipoprotein receptor (VLDLR) and signals via the Reelin-
RT   signaling pathway.";
RL   J. Biol. Chem. 289:4161-4172(2014).
CC   -!- FUNCTION: [Isoform 1]: Functions as extracellular chaperone that
CC       prevents aggregation of non native proteins (PubMed:11123922,
CC       PubMed:19535339). Prevents stress-induced aggregation of blood plasma
CC       proteins (PubMed:11123922, PubMed:12176985, PubMed:17260971,
CC       PubMed:19996109). Inhibits formation of amyloid fibrils by APP, APOC2,
CC       B2M, CALCA, CSN3, SNCA and aggregation-prone LYZ variants (in vitro)
CC       (PubMed:12047389, PubMed:17412999, PubMed:17407782). Does not require
CC       ATP (PubMed:11123922). Maintains partially unfolded proteins in a state
CC       appropriate for subsequent refolding by other chaperones, such as
CC       HSPA8/HSC70 (PubMed:11123922). Does not refold proteins by itself
CC       (PubMed:11123922). Binding to cell surface receptors triggers
CC       internalization of the chaperone-client complex and subsequent
CC       lysosomal or proteasomal degradation (PubMed:21505792). Protects cells
CC       against apoptosis and against cytolysis by complement (PubMed:2780565).
CC       Intracellular forms interact with ubiquitin and SCF (SKP1-CUL1-F-box
CC       protein) E3 ubiquitin-protein ligase complexes and promote the
CC       ubiquitination and subsequent proteasomal degradation of target
CC       proteins (PubMed:20068069). Promotes proteasomal degradation of COMMD1
CC       and IKBKB (PubMed:20068069). Modulates NF-kappa-B transcriptional
CC       activity (PubMed:12882985). A mitochondrial form suppresses BAX-
CC       dependent release of cytochrome c into the cytoplasm and inhibit
CC       apoptosis (PubMed:16113678, PubMed:17689225). Plays a role in the
CC       regulation of cell proliferation (PubMed:19137541). An intracellular
CC       form suppresses stress-induced apoptosis by stabilizing mitochondrial
CC       membrane integrity through interaction with HSPA5 (PubMed:22689054).
CC       Secreted form does not affect caspase or BAX-mediated intrinsic
CC       apoptosis and TNF-induced NF-kappa-B-activity (PubMed:24073260).
CC       Secreted form act as an important modulator during neuronal
CC       differentiation through interaction with STMN3 (By similarity). Plays a
CC       role in the clearance of immune complexes that arise during cell injury
CC       (By similarity). {ECO:0000250|UniProtKB:P05371,
CC       ECO:0000250|UniProtKB:Q06890, ECO:0000269|PubMed:11123922,
CC       ECO:0000269|PubMed:12047389, ECO:0000269|PubMed:12176985,
CC       ECO:0000269|PubMed:12882985, ECO:0000269|PubMed:16113678,
CC       ECO:0000269|PubMed:17260971, ECO:0000269|PubMed:17407782,
CC       ECO:0000269|PubMed:17412999, ECO:0000269|PubMed:17689225,
CC       ECO:0000269|PubMed:19137541, ECO:0000269|PubMed:19535339,
CC       ECO:0000269|PubMed:19996109, ECO:0000269|PubMed:20068069,
CC       ECO:0000269|PubMed:21505792, ECO:0000269|PubMed:22689054,
CC       ECO:0000269|PubMed:24073260, ECO:0000269|PubMed:2780565}.
CC   -!- FUNCTION: [Isoform 6]: Does not affect caspase or BAX-mediated
CC       intrinsic apoptosis and TNF-induced NF-kappa-B-activity.
CC       {ECO:0000269|PubMed:24073260}.
CC   -!- FUNCTION: [Isoform 4]: Does not affect caspase or BAX-mediated
CC       intrinsic apoptosis and TNF-induced NF-kappa-B-activity
CC       (PubMed:24073260). Promotes cell death through interaction with BCL2L1
CC       that releases and activates BAX (PubMed:21567405).
CC       {ECO:0000269|PubMed:21567405, ECO:0000269|PubMed:24073260}.
CC   -!- SUBUNIT: Antiparallel disulfide-linked heterodimer of an alpha chain
CC       and a beta chain (PubMed:12047389, PubMed:1491011, PubMed:1551440,
CC       PubMed:2780565, PubMed:2387851, PubMed:8328966). Self-associates and
CC       forms higher oligomers (PubMed:1903064). Interacts with a broad range
CC       of misfolded proteins, including APP, APOC2 and LYZ (PubMed:17407782,
CC       PubMed:8328966, PubMed:17412999). Slightly acidic pH promotes
CC       interaction with misfolded proteins (PubMed:12176985). Forms high-
CC       molecular weight oligomers upon interaction with misfolded proteins
CC       (PubMed:19535339). Interacts with APOA1, LRP2, CLUAP1 and PON1
CC       (PubMed:15480429, PubMed:17260971, PubMed:1742316, PubMed:8292612,
CC       PubMed:1903064). Interacts with the complement complex
CC       (PubMed:2601725). Interacts (via alpha chain) with XRCC6 (By
CC       similarity). Interacts with SYVN1, COMMD1, BTRC, CUL1 and with
CC       ubiquitin and SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase
CC       complexes (PubMed:17451556, PubMed:20068069). Interacts (via alpha
CC       chain) with BAX in stressed cells, where BAX undergoes a conformation
CC       change leading to association with the mitochondrial membrane
CC       (PubMed:16113678). Does not interact with BAX in unstressed cells
CC       (PubMed:16113678). Found in a complex with LTF, CLU, EPPIN and SEMG1
CC       (PubMed:17567961). Interacts (immaturely glycosylated pre-secreted
CC       form) with HSPA5; this interaction promotes CLU stability and
CC       facilitates stress-induced CLU retrotranslocation from the secretory
CC       pathway to the mitochondria, thereby reducing stress-induced apoptosis
CC       by stabilizing mitochondrial membrane integrity (PubMed:22689054).
CC       Interacts (isoform 4) with BCL2L1; this interaction releases and
CC       activates BAX and promotes cell death (PubMed:21567405). Interacts with
CC       TGFBR2 and ACVR1 (PubMed:8555189). Interacts (secreted form) with
CC       STMN3; this interaction may act as an important modulator during
CC       neuronal differentiation (By similarity). Interacts with VLDLR and LRP8
CC       (PubMed:24381170). {ECO:0000250|UniProtKB:P05371,
CC       ECO:0000250|UniProtKB:Q06890, ECO:0000269|PubMed:12047389,
CC       ECO:0000269|PubMed:12176985, ECO:0000269|PubMed:1491011,
CC       ECO:0000269|PubMed:15480429, ECO:0000269|PubMed:1551440,
CC       ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:17260971,
CC       ECO:0000269|PubMed:17407782, ECO:0000269|PubMed:17412999,
CC       ECO:0000269|PubMed:1742316, ECO:0000269|PubMed:17451556,
CC       ECO:0000269|PubMed:17567961, ECO:0000269|PubMed:1903064,
CC       ECO:0000269|PubMed:19535339, ECO:0000269|PubMed:1974459,
CC       ECO:0000269|PubMed:20068069, ECO:0000269|PubMed:21567405,
CC       ECO:0000269|PubMed:22689054, ECO:0000269|PubMed:2387851,
CC       ECO:0000269|PubMed:24381170, ECO:0000269|PubMed:2601725,
CC       ECO:0000269|PubMed:2780565, ECO:0000269|PubMed:8292612,
CC       ECO:0000269|PubMed:8328966, ECO:0000269|PubMed:8555189}.
CC   -!- INTERACTION:
CC       P10909; P18509: ADCYAP1; NbExp=4; IntAct=EBI-1104674, EBI-8588930;
CC       P10909; P05067: APP; NbExp=3; IntAct=EBI-1104674, EBI-77613;
CC       P10909; PRO_0000000093 [P05067]: APP; NbExp=4; IntAct=EBI-1104674, EBI-2431589;
CC       P10909; Q9NRI5: DISC1; NbExp=4; IntAct=EBI-1104674, EBI-529989;
CC       P10909; P01100: FOS; NbExp=2; IntAct=EBI-1104674, EBI-852851;
CC       P10909; P30101: PDIA3; NbExp=2; IntAct=EBI-1104674, EBI-979862;
CC       P10909; P37231: PPARG; NbExp=3; IntAct=EBI-1104674, EBI-781384;
CC       P10909; P37840: SNCA; NbExp=4; IntAct=EBI-1104674, EBI-985879;
CC       P10909-4; Q07817-1: BCL2L1; NbExp=6; IntAct=EBI-4322678, EBI-287195;
CC       P10909-5; PRO_0000000092 [P05067]: APP; NbExp=2; IntAct=EBI-10961636, EBI-821758;
CC       P10909-5; Q9NZV6: MSRB1; NbExp=10; IntAct=EBI-10961636, EBI-12330065;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Secreted
CC       {ECO:0000269|PubMed:11123922, ECO:0000269|PubMed:17260971,
CC       ECO:0000269|PubMed:17412999, ECO:0000269|PubMed:17451556,
CC       ECO:0000269|PubMed:2387851, ECO:0000269|PubMed:24073260,
CC       ECO:0000269|PubMed:2780565, ECO:0000269|PubMed:3154963,
CC       ECO:0000269|PubMed:8292612, ECO:0000269|PubMed:8328966}. Note=Can
CC       retrotranslocate from the secretory compartments to the cytosol upon
CC       cellular stress. {ECO:0000269|PubMed:17451556}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Cytoplasm
CC       {ECO:0000269|PubMed:24073260}. Note=Keeps cytoplasmic localization in
CC       stressed and unstressed cell. {ECO:0000269|PubMed:24073260}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 6]: Cytoplasm
CC       {ECO:0000269|PubMed:24073260}. Note=Keeps cytoplasmic localization in
CC       stressed and unstressed cell. {ECO:0000269|PubMed:24073260}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12551933,
CC       ECO:0000269|PubMed:19137541}. Cytoplasm {ECO:0000269|PubMed:12551933,
CC       ECO:0000269|PubMed:17689225, ECO:0000269|PubMed:19137541,
CC       ECO:0000269|PubMed:20068069, ECO:0000269|PubMed:22689054,
CC       ECO:0000269|PubMed:24073260}. Mitochondrion membrane; Peripheral
CC       membrane protein; Cytoplasmic side {ECO:0000269|PubMed:17689225}.
CC       Cytoplasm, cytosol {ECO:0000269|PubMed:17451556,
CC       ECO:0000269|PubMed:22689054, ECO:0000269|PubMed:24073260}. Microsome
CC       {ECO:0000269|PubMed:22689054}. Endoplasmic reticulum
CC       {ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:22689054}.
CC       Mitochondrion {ECO:0000269|PubMed:16113678,
CC       ECO:0000269|PubMed:22689054}. Mitochondrion membrane
CC       {ECO:0000269|PubMed:16113678, ECO:0000269|PubMed:17689225}. Cytoplasm,
CC       perinuclear region {ECO:0000250|UniProtKB:P05371}. Cytoplasmic vesicle,
CC       secretory vesicle, chromaffin granule {ECO:0000250}. Note=Secreted
CC       isoforms can retrotranslocate from the secretory compartments to the
CC       cytosol upon cellular stress (PubMed:17451556). Detected in perinuclear
CC       foci that may be aggresomes containing misfolded, ubiquitinated
CC       proteins (PubMed:20068069). Detected at the mitochondrion membrane upon
CC       induction of apoptosis (PubMed:17689225). Under ER stress, a immaturely
CC       glycosylated pre-secreted form retrotranslocates from the endoplasmic
CC       reticulum (ER)-Golgi network to the cytoplasm to localize in the
CC       mitochondria through HSPA5 interaction (PubMed:22689054). ER stress
CC       reduces secretion (PubMed:22689054). Under the stress, minor amounts of
CC       non-secreted forms accumulate in cytoplasm (PubMed:24073260,
CC       PubMed:22689054, PubMed:17451556). Non-secreted forms emerge mainly
CC       from failed translocation, alternative splicing or non-canonical
CC       initiation start codon (PubMed:24073260, PubMed:12551933).
CC       {ECO:0000269|PubMed:12551933, ECO:0000269|PubMed:17451556,
CC       ECO:0000269|PubMed:17689225, ECO:0000269|PubMed:20068069,
CC       ECO:0000269|PubMed:22689054, ECO:0000269|PubMed:24073260}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=2, CLU35, sCLU;
CC         IsoId=P10909-1; Sequence=Displayed;
CC       Name=2; Synonyms=1, CLU34;
CC         IsoId=P10909-2; Sequence=VSP_037661;
CC       Name=3;
CC         IsoId=P10909-3; Sequence=VSP_041475;
CC       Name=4; Synonyms=nCLU {ECO:0000303|PubMed:12551933};
CC         IsoId=P10909-4; Sequence=VSP_041476;
CC       Name=5; Synonyms=CLU36;
CC         IsoId=P10909-5; Sequence=VSP_041477;
CC       Name=6;
CC         IsoId=P10909-6; Sequence=VSP_060188, VSP_060192;
CC   -!- TISSUE SPECIFICITY: Detected in blood plasma, cerebrospinal fluid,
CC       milk, seminal plasma and colon mucosa. Detected in the germinal center
CC       of colon lymphoid nodules and in colon parasympathetic ganglia of the
CC       Auerbach plexus (at protein level). Ubiquitous. Detected in brain,
CC       testis, ovary, liver and pancreas, and at lower levels in kidney,
CC       heart, spleen and lung. {ECO:0000269|PubMed:11123922,
CC       ECO:0000269|PubMed:17260971, ECO:0000269|PubMed:17322305,
CC       ECO:0000269|PubMed:17412999, ECO:0000269|PubMed:1974459,
CC       ECO:0000269|PubMed:2387851, ECO:0000269|PubMed:2780565,
CC       ECO:0000269|PubMed:3154963, ECO:0000269|PubMed:8181474,
CC       ECO:0000269|PubMed:8292612, ECO:0000269|PubMed:8328966}.
CC   -!- INDUCTION: Up-regulated in response to enterovirus 71 (EV71) infection
CC       (at protein level) (PubMed:16548883). Up-regulated by agents that
CC       induce apoptosis, both at mRNA and protein level (PubMed:17689225).
CC       Isoform 1 is up-regulated by androgen (PubMed:17148459). Isoform 2 is
CC       down-regulated by androgen (PubMed:17148459).
CC       {ECO:0000269|PubMed:16548883, ECO:0000269|PubMed:17148459,
CC       ECO:0000269|PubMed:17689225}.
CC   -!- PTM: Proteolytically cleaved on its way through the secretory system,
CC       probably within the Golgi lumen (PubMed:2387851). Proteolytic cleavage
CC       is not necessary for its chaperone activity (PubMed:25402950). All non-
CC       secreted forms are not proteolytically cleaved (PubMed:24073260).
CC       Chaperone activity of uncleaved forms is dependent on a non-reducing
CC       environment (PubMed:25402950). {ECO:0000269|PubMed:2387851,
CC       ECO:0000269|PubMed:24073260, ECO:0000269|PubMed:25402950}.
CC   -!- PTM: Polyubiquitinated, leading to proteasomal degradation
CC       (PubMed:17451556, PubMed:19137541). Under cellular stress, the
CC       intracellular level of cleaved form is reduced due to proteasomal
CC       degradation (PubMed:17451556). {ECO:0000269|PubMed:17451556,
CC       ECO:0000269|PubMed:19137541}.
CC   -!- PTM: Extensively glycosylated with sulfated N-linked carbohydrates
CC       (PubMed:17260971, PubMed:2387851). About 30% of the protein mass is
CC       comprised of complex N-linked carbohydrate (PubMed:2387851).
CC       Endoplasmic reticulum (ER) stress induces changes in glycosylation
CC       status and increases level of hypoglycosylated forms (PubMed:22689054).
CC       Core carbohydrates are essential for chaperone activity
CC       (PubMed:25402950). Non-secreted forms are hypoglycosylated or
CC       unglycosylated (PubMed:24073260). {ECO:0000269|PubMed:17260971,
CC       ECO:0000269|PubMed:22689054, ECO:0000269|PubMed:2387851,
CC       ECO:0000269|PubMed:24073260, ECO:0000269|PubMed:25402950}.
CC   -!- MISCELLANEOUS: [Isoform 1]: Major isoform. Major isoform. Detectable at
CC       protein level in stressed and unstressed cells (PubMed:24073260).
CC       {ECO:0000269|PubMed:24073260}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Minor isoform that has been detected in a
CC       breast cancer cell line, but not in any other tissues or cell lines
CC       (PubMed:12551933). Not glycosylated. Not detected in unstressed cells.
CC       Detectable at low level in stressed cells (PubMed:24073260).
CC       {ECO:0000269|PubMed:24073260, ECO:0000303|PubMed:12551933}.
CC   -!- MISCELLANEOUS: [Isoform 6]: Translated from an unconventional
CC       translation initiation site CTG (PubMed:24073260). Not glycosylated
CC       (PubMed:24073260). Not detected in unstressed cells. Detectable at low
CC       level in stressed cells (PubMed:24073260).
CC       {ECO:0000269|PubMed:24073260}.
CC   -!- SIMILARITY: Belongs to the clusterin family. {ECO:0000305}.
CC   -!- CAUTION: Isoform 4 has been previously detected in cytosol and in the
CC       nuclei of apoptotic cells and promoted apoptosis following irradiation
CC       (PubMed:12551933). However the nuclear localization and apoptosis
CC       promotion has not been confirmed in other cell types (PubMed:24073260).
CC       {ECO:0000269|PubMed:12551933, ECO:0000269|PubMed:24073260}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA35692.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAB06508.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAB06508.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence.; Evidence={ECO:0000305};
CC       Sequence=AAH10514.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAH19588.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAP88927.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=AAP88927.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAT08041.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAG36598.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA32847.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/clu/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/40107/CLU";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M25915; AAA35692.1; ALT_INIT; mRNA.
DR   EMBL; M63379; AAB06507.1; -; Genomic_DNA.
DR   EMBL; M63376; AAB06507.1; JOINED; Genomic_DNA.
DR   EMBL; M63377; AAB06507.1; JOINED; Genomic_DNA.
DR   EMBL; M63378; AAB06507.1; JOINED; Genomic_DNA.
DR   EMBL; M64722; AAB06508.1; ALT_SEQ; mRNA.
DR   EMBL; AK093399; BAG52708.1; -; mRNA.
DR   EMBL; AK313870; BAG36598.1; ALT_INIT; mRNA.
DR   EMBL; CR599675; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BX648414; CAI45990.1; -; mRNA.
DR   EMBL; AY341244; AAP88927.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF311103; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC010514; AAH10514.1; ALT_INIT; mRNA.
DR   EMBL; BC019588; AAH19588.1; ALT_INIT; mRNA.
DR   EMBL; BU150467; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; J02908; AAA51765.1; -; mRNA.
DR   EMBL; M74816; AAA60321.1; -; mRNA.
DR   EMBL; L00974; AAA60567.1; -; Genomic_DNA.
DR   EMBL; X14723; CAA32847.1; ALT_INIT; mRNA.
DR   EMBL; AY513288; AAT08041.1; ALT_INIT; mRNA.
DR   CCDS; CCDS47832.1; -. [P10909-1]
DR   PIR; S43646; A41386.
DR   RefSeq; NP_001822.3; NM_001831.3. [P10909-1]
DR   AlphaFoldDB; P10909; -.
DR   SMR; P10909; -.
DR   BioGRID; 107603; 272.
DR   DIP; DIP-37546N; -.
DR   IntAct; P10909; 166.
DR   MINT; P10909; -.
DR   STRING; 9606.ENSP00000315130; -.
DR   DrugBank; DB09130; Copper.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   DrugBank; DB14533; Zinc chloride.
DR   DrugBank; DB14548; Zinc sulfate, unspecified form.
DR   GuidetoPHARMACOLOGY; 3195; -.
DR   CarbonylDB; P10909; -.
DR   GlyConnect; 759; 142 N-Linked glycans (6 sites).
DR   GlyCosmos; P10909; 7 sites, 157 glycans.
DR   GlyGen; P10909; 12 sites, 158 N-linked glycans (6 sites), 3 O-linked glycans (4 sites).
DR   iPTMnet; P10909; -.
DR   PhosphoSitePlus; P10909; -.
DR   BioMuta; CLU; -.
DR   DMDM; 116533; -.
DR   DOSAC-COBS-2DPAGE; P10909; -.
DR   OGP; P10909; -.
DR   REPRODUCTION-2DPAGE; IPI00291262; -.
DR   SWISS-2DPAGE; P10909; -.
DR   CPTAC; CPTAC-478; -.
DR   CPTAC; CPTAC-479; -.
DR   CPTAC; CPTAC-661; -.
DR   CPTAC; CPTAC-662; -.
DR   CPTAC; CPTAC-728; -.
DR   CPTAC; non-CPTAC-1096; -.
DR   CPTAC; non-CPTAC-1097; -.
DR   CPTAC; non-CPTAC-1098; -.
DR   EPD; P10909; -.
DR   jPOST; P10909; -.
DR   MassIVE; P10909; -.
DR   MaxQB; P10909; -.
DR   PaxDb; P10909; -.
DR   PeptideAtlas; P10909; -.
DR   PRIDE; P10909; -.
DR   ProteomicsDB; 52663; -. [P10909-1]
DR   ProteomicsDB; 52664; -. [P10909-2]
DR   ProteomicsDB; 52665; -. [P10909-3]
DR   ProteomicsDB; 52666; -. [P10909-4]
DR   ProteomicsDB; 52667; -. [P10909-5]
DR   ABCD; P10909; 1 sequenced antibody.
DR   Antibodypedia; 631; 1338 antibodies from 51 providers.
DR   CPTC; P10909; 1 antibody.
DR   DNASU; 1191; -.
DR   Ensembl; ENST00000316403.15; ENSP00000315130.10; ENSG00000120885.22. [P10909-1]
DR   Ensembl; ENST00000405140.7; ENSP00000385419.3; ENSG00000120885.22. [P10909-1]
DR   Ensembl; ENST00000523500.5; ENSP00000429620.1; ENSG00000120885.22. [P10909-1]
DR   GeneID; 1191; -.
DR   KEGG; hsa:1191; -.
DR   MANE-Select; ENST00000316403.15; ENSP00000315130.10; NM_001831.4; NP_001822.3.
DR   UCSC; uc003xfw.3; human. [P10909-1]
DR   AGR; HGNC:2095; -.
DR   CTD; 1191; -.
DR   DisGeNET; 1191; -.
DR   GeneCards; CLU; -.
DR   HGNC; HGNC:2095; CLU.
DR   HPA; ENSG00000120885; Tissue enhanced (brain, liver).
DR   MIM; 185430; gene.
DR   neXtProt; NX_P10909; -.
DR   NIAGADS; ENSG00000120885; -.
DR   OpenTargets; ENSG00000120885; -.
DR   PharmGKB; PA26620; -.
DR   VEuPathDB; HostDB:ENSG00000120885; -.
DR   eggNOG; ENOG502RBQP; Eukaryota.
DR   GeneTree; ENSGT00530000063668; -.
DR   HOGENOM; CLU_042162_2_0_1; -.
DR   InParanoid; P10909; -.
DR   OMA; QGSKYIN; -.
DR   OrthoDB; 4321242at2759; -.
DR   PhylomeDB; P10909; -.
DR   TreeFam; TF333030; -.
DR   PathwayCommons; P10909; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-166665; Terminal pathway of complement.
DR   Reactome; R-HSA-6803157; Antimicrobial peptides.
DR   Reactome; R-HSA-977606; Regulation of Complement cascade.
DR   SignaLink; P10909; -.
DR   SIGNOR; P10909; -.
DR   BioGRID-ORCS; 1191; 13 hits in 1159 CRISPR screens.
DR   ChiTaRS; CLU; human.
DR   GeneWiki; Clusterin; -.
DR   GenomeRNAi; 1191; -.
DR   Pharos; P10909; Tbio.
DR   PRO; PR:P10909; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; P10909; protein.
DR   Bgee; ENSG00000120885; Expressed in lateral globus pallidus and 207 other tissues.
DR   ExpressionAtlas; P10909; baseline and differential.
DR   Genevisible; P10909; HS.
DR   GO; GO:0097440; C:apical dendrite; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0042583; C:chromaffin granule; IEA:UniProtKB-SubCell.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; HDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0097418; C:neurofibrillary tangle; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0099020; C:perinuclear endoplasmic reticulum lumen; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0034366; C:spherical high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0001540; F:amyloid-beta binding; IDA:ARUK-UCL.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; IPI:ARUK-UCL.
DR   GO; GO:0051787; F:misfolded protein binding; IDA:UniProtKB.
DR   GO; GO:0140597; F:protein carrier chaperone; IDA:ARUK-UCL.
DR   GO; GO:0046982; F:protein heterodimerization activity; TAS:ARUK-UCL.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:ARUK-UCL.
DR   GO; GO:0051087; F:protein-folding chaperone binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:ARUK-UCL.
DR   GO; GO:0048156; F:tau protein binding; IPI:ARUK-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; IMP:UniProtKB.
DR   GO; GO:0000902; P:cell morphogenesis; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0032286; P:central nervous system myelin maintenance; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0051131; P:chaperone-mediated protein complex assembly; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0061077; P:chaperone-mediated protein folding; IDA:UniProtKB.
DR   GO; GO:0006956; P:complement activation; TAS:ProtInc.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0002434; P:immune complex clearance; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006629; P:lipid metabolic process; NAS:ProtInc.
DR   GO; GO:0001774; P:microglial cell activation; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0061518; P:microglial cell proliferation; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1905907; P:negative regulation of amyloid fibril formation; IDA:ARUK-UCL.
DR   GO; GO:1902430; P:negative regulation of amyloid-beta formation; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1902230; P:negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage; IMP:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:ARUK-UCL.
DR   GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IDA:ARUK-UCL.
DR   GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; TAS:ARUK-UCL.
DR   GO; GO:1903573; P:negative regulation of response to endoplasmic reticulum stress; IMP:ARUK-UCL.
DR   GO; GO:1905908; P:positive regulation of amyloid fibril formation; TAS:ARUK-UCL.
DR   GO; GO:1902004; P:positive regulation of amyloid-beta formation; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:ARUK-UCL.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:1902998; P:positive regulation of neurofibrillary tangle assembly; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:1901216; P:positive regulation of neuron death; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0031334; P:positive regulation of protein-containing complex assembly; IDA:ARUK-UCL.
DR   GO; GO:0048260; P:positive regulation of receptor-mediated endocytosis; IGI:ARUK-UCL.
DR   GO; GO:1902949; P:positive regulation of tau-protein kinase activity; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0017038; P:protein import; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0050821; P:protein stabilization; IDA:UniProtKB.
DR   GO; GO:0061740; P:protein targeting to lysosome involved in chaperone-mediated autophagy; IDA:ARUK-UCL.
DR   GO; GO:1900221; P:regulation of amyloid-beta clearance; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:1901214; P:regulation of neuron death; IDA:Alzheimers_University_of_Toronto.
DR   GO; GO:1902847; P:regulation of neuronal signal transduction; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0001836; P:release of cytochrome c from mitochondria; IC:BHF-UCL.
DR   GO; GO:0051788; P:response to misfolded protein; IDA:BHF-UCL.
DR   GO; GO:0009615; P:response to virus; IEP:UniProtKB.
DR   GO; GO:0043691; P:reverse cholesterol transport; TAS:BHF-UCL.
DR   InterPro; IPR016016; Clusterin.
DR   InterPro; IPR000753; Clusterin-like.
DR   InterPro; IPR016015; Clusterin_C.
DR   InterPro; IPR033986; Clusterin_CS.
DR   InterPro; IPR016014; Clusterin_N.
DR   PANTHER; PTHR10970; CLUSTERIN; 1.
DR   PANTHER; PTHR10970:SF1; CLUSTERIN; 1.
DR   Pfam; PF01093; Clusterin; 1.
DR   PIRSF; PIRSF002368; Clusterin; 1.
DR   SMART; SM00035; CLa; 1.
DR   SMART; SM00030; CLb; 1.
DR   PROSITE; PS00492; CLUSTERIN_1; 1.
DR   PROSITE; PS00493; CLUSTERIN_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Apoptosis; Chaperone; Complement pathway; Cytoplasm;
KW   Cytoplasmic vesicle; Direct protein sequencing; Disulfide bond;
KW   Endoplasmic reticulum; Glycoprotein; Immunity; Innate immunity; Membrane;
KW   Microsome; Mitochondrion; Nucleus; Phosphoprotein; Reference proteome;
KW   Secreted; Signal; Ubl conjugation.
FT   SIGNAL          1..22
FT                   /evidence="ECO:0000269|PubMed:1903064,
FT                   ECO:0000269|PubMed:2387851, ECO:0000269|PubMed:2601725,
FT                   ECO:0000269|PubMed:2780565, ECO:0000269|PubMed:3154963,
FT                   ECO:0000269|PubMed:8328966"
FT   CHAIN           23..449
FT                   /note="Clusterin"
FT                   /id="PRO_0000005529"
FT   CHAIN           23..227
FT                   /note="Clusterin beta chain"
FT                   /evidence="ECO:0000269|PubMed:2387851,
FT                   ECO:0000269|PubMed:2721499"
FT                   /id="PRO_0000005530"
FT   CHAIN           228..449
FT                   /note="Clusterin alpha chain"
FT                   /evidence="ECO:0000269|PubMed:2387851,
FT                   ECO:0000269|PubMed:2721499"
FT                   /id="PRO_0000005531"
FT   MOTIF           78..81
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250|UniProtKB:Q06890"
FT   MOTIF           443..447
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250|UniProtKB:Q06890"
FT   SITE            227..228
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000269|PubMed:25402950"
FT   MOD_RES         133
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         396
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   CARBOHYD        86
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:1551440,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19139490,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:9336835"
FT   CARBOHYD        103
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:1551440,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:2721499, ECO:0000269|PubMed:9336835"
FT   CARBOHYD        145
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:1551440,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:2721499, ECO:0000269|PubMed:9336835"
FT   CARBOHYD        291
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:1551440,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:18780401,
FT                   ECO:0000269|PubMed:2721499, ECO:0000269|PubMed:9336835"
FT   CARBOHYD        354
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519,
FT                   ECO:0000269|PubMed:14760718, ECO:0000269|PubMed:1551440,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218,
FT                   ECO:0000269|PubMed:9336835"
FT   CARBOHYD        374
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14760718,
FT                   ECO:0000269|PubMed:1551440, ECO:0000269|PubMed:16263699,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:16740002,
FT                   ECO:0000269|PubMed:18780401, ECO:0000269|PubMed:19139490,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19838169,
FT                   ECO:0000269|PubMed:9336835"
FT   DISULFID        102..313
FT                   /note="Interchain (between beta and alpha chains)"
FT   DISULFID        113..305
FT                   /note="Interchain (between beta and alpha chains)"
FT   DISULFID        116..302
FT                   /note="Interchain (between beta and alpha chains)"
FT   DISULFID        121..295
FT                   /note="Interchain (between beta and alpha chains)"
FT   DISULFID        129..285
FT                   /note="Interchain (between beta and alpha chains)"
FT   VAR_SEQ         1..175
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_041475"
FT   VAR_SEQ         1..33
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_041476"
FT   VAR_SEQ         1..20
FT                   /note="Missing (in isoform 6)"
FT                   /id="VSP_060188"
FT   VAR_SEQ         1
FT                   /note="M -> MQVCSQPQRGCVREQSAINTAPPSAHNAASPGGARGHRVPLTEACKD
FT                   SRIGGM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:17974005,
FT                   ECO:0000303|PubMed:2780565, ECO:0000303|Ref.5"
FT                   /id="VSP_037661"
FT   VAR_SEQ         1
FT                   /note="M -> MEACKDSRIGGM (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_041477"
FT   VAR_SEQ         21
FT                   /note="L -> M (in isoform 6)"
FT                   /id="VSP_060192"
FT   VARIANT         317
FT                   /note="N -> H (in dbSNP:rs9331936)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_019366"
FT   VARIANT         328
FT                   /note="D -> N (in dbSNP:rs9331938)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_019367"
FT   VARIANT         396
FT                   /note="S -> L (in dbSNP:rs13494)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_019368"
FT   MUTAGEN         86
FT                   /note="N->Q: Decreases molecular mass of beta chain; when
FT                   associated with Q-103 and Q-145."
FT                   /evidence="ECO:0000269|PubMed:22689054"
FT   MUTAGEN         103
FT                   /note="N->Q: Decreases molecular mass of beta chain; when
FT                   associated with Q-86 and Q-145."
FT                   /evidence="ECO:0000269|PubMed:22689054"
FT   MUTAGEN         145
FT                   /note="N->Q: Decreases molecular mass of beta chain; when
FT                   associated with Q-86 and Q-103."
FT                   /evidence="ECO:0000269|PubMed:22689054"
FT   MUTAGEN         226
FT                   /note="V->T: Does not affect proteolytic cleavage."
FT                   /evidence="ECO:0000269|PubMed:25402950"
FT   MUTAGEN         227
FT                   /note="R->Q: Affects proteolytic cleavage."
FT                   /evidence="ECO:0000269|PubMed:25402950"
FT   MUTAGEN         291
FT                   /note="N->Q: Decreases molecular mass of alpha chain; when
FT                   associated with Q-354 and Q-374. Decreases secretion; when
FT                   associated with Q-354 and Q-374."
FT                   /evidence="ECO:0000269|PubMed:22689054"
FT   MUTAGEN         354
FT                   /note="N->Q: Decreases molecular mass of alpha chain; when
FT                   associated with Q-291 and Q-374. Decreases secretion; when
FT                   associated with Q-291 and Q-374."
FT                   /evidence="ECO:0000269|PubMed:22689054"
FT   MUTAGEN         374
FT                   /note="N->Q: Decreases molecular mass of alpha chain; when
FT                   associated with Q-291 and Q-354. Decreases secretion; when
FT                   associated with Q-291 and Q-354."
FT                   /evidence="ECO:0000269|PubMed:22689054"
FT   CONFLICT        28
FT                   /note="D -> S (in Ref. 10; AA sequence and 14; AA
FT                   sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        47
FT                   /note="Q -> H (in Ref. 11; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        52
FT                   /note="G -> Q (in Ref. 11; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        172
FT                   /note="M -> V (in Ref. 6; CAI45990)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        224
FT                   /note="R -> L (in Ref. 4; BAG36598)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        305
FT                   /note="C -> M (in Ref. 10; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        388
FT                   /note="T -> M (in Ref. 6; CAI45990)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        411
FT                   /note="D -> G (in Ref. 4; BAG36598)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   449 AA;  52495 MW;  9583DE4CCECC169F CRC64;
     MMKTLLLFVG LLLTWESGQV LGDQTVSDNE LQEMSNQGSK YVNKEIQNAV NGVKQIKTLI
     EKTNEERKTL LSNLEEAKKK KEDALNETRE SETKLKELPG VCNETMMALW EECKPCLKQT
     CMKFYARVCR SGSGLVGRQL EEFLNQSSPF YFWMNGDRID SLLENDRQQT HMLDVMQDHF
     SRASSIIDEL FQDRFFTREP QDTYHYLPFS LPHRRPHFFF PKSRIVRSLM PFSPYEPLNF
     HAMFQPFLEM IHEAQQAMDI HFHSPAFQHP PTEFIREGDD DRTVCREIRH NSTGCLRMKD
     QCDKCREILS VDCSTNNPSQ AKLRRELDES LQVAERLTRK YNELLKSYQW KMLNTSSLLE
     QLNEQFNWVS RLANLTQGED QYYLRVTTVA SHTSDSDVPS GVTEVVVKLF DSDPITVTVP
     VEVSRKNPKF METVAEKALQ EYRKKHREE
//
